CompletedNot Applicable

Immunogenicity and Thrombotic Potential of Circulating Protamine-heparin Complexes in Cardiac Surgery Patients

Austria160 participantsStarted 2019-01-07

Plain-language summary

The primary aim of this study was to describe the prevalence and time course of the occurrence of protamine/heparin antibodies in patients undergoing cardiac surgery on cardiopulmonary bypass. The second aim was to identify triggers of immunization. The third aim of this study was to evaluate a potential clinical impact of protamine/heparin antibodies and their platelet-activating properties leading to thromboembolism and other adverse outcomes.

Who can participate

Age range18 Years – 99 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * age ≥ 18 years * cardiac surgery on cardiopulmonary bypass Exclusion Criteria: * cardiac surgery without cardiopulmonary bypass * age \< 18 years * no written consent

What they're measuring

prevalence of protamine/heparin antibodies

Timeframe: preoperatively until postoperative day 10

Trial details

NCT IDNCT06565364

SponsorMedical University of Vienna

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2023-03-31

View on ClinicalTrials.gov More Thrombocytopenia trials